Interest in platinum-based therapies was renewed with the observation that BRCA1 deficient cell lines have a higher sensitivity to DNA crosslinking agents, such as cisplatin, compared with other breast cancer cell lines (2). The gene discussed is BRCA1; the disease is breast carcinoma.